Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors

Am J Hematol. 2011 Jun;86(6):523-5. doi: 10.1002/ajh.22020.
No abstract available

Publication types

  • Multicenter Study
  • Validation Study

MeSH terms

  • Female
  • Humans
  • Italy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Male
  • Middle Aged
  • Predictive Value of Tests*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Risk Assessment / methods
  • Survival Analysis

Substances

  • Protein Kinase Inhibitors